top of page
A-desktop-1920x400.png

ENGRAFTIS

Changing the paradigm of bone marrow transplantation

The disease

Allogenic HSCT (Hematopoietic Stem Cell Transplantation) can cure and/or prolong life in a broad range of hematologic disorders

​About 30,000 allogenic HSCT per year (US+EU)​

However, many patients are at risk of HSCT complications leading to excess mortality and/or increase of treatment costs

Our solution

A unique artificial bone marrow niche to enhance HSCT

  • Injectable therapeutic implant ​

  • Dual mechanism: restoration of signaling pathways and recreation of a favorable bone marrow environment​

  • Patent protection through 2046,

      ensuring a strong barrier to entry

A pioneer technology

First Preclinical validation completed

dessin visuel
dessin visuel
logo
logo

First indication: Poor Graft Function (PGF)

Major Medical need

Significant excess mortality: 1-year survival rate of 20–50% vs. 90% in cases of successful graft*

Extension

Cell homing platform for other tissue

regeneration applications

* Zhao et al. Biology of Blood and Marrow Transplantation, 2019

bottom of page